• In early August 2026, Personalis, Inc. reported past second-quarter results showing sales of US$22.36 million versus US$17.20 million a year earlier, while net loss widened to US$31.68 million and basic loss per share from continuing operations increased to US$0.30 from US$0.23.
• Over the first six months of 2026, sales were essentially flat year over year at about US$37.83 million, but the net loss grew sharply to US$61.72 million with a higher basic loss per share, underscoring rising costs relative to revenue.
• Against this backdrop of quarterly revenue growth but wider losses, we’ll now examine how the latest results may influence Personalis’ investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Personalis Investment Narrative Recap

To own Personalis, you generally need to believe its ultrasensitive MRD platform can convert scientific traction and new reimbursement wins into a much larger, more durable testing business. The latest results show revenue progress but also a sharply higher net loss, which keeps high cash burn and potential future dilution as the key near term risk. For now, the August earnings do not materially change the immediate deal catalyst around the planned Tempus acquisition.

The most relevant recent announcement here is Personalis reaffirming its 2026 guidance in May, with full year revenue still guided to US$78.0–80.0 million and a net loss of about US$105.0 million. With first half sales of US$37.83 million and losses already at US$61.72 million, investors may watch closely whether second half performance and expense trends stay aligned with that guidance or add pressure to the existing risk around ongoing operating losses and funding needs.

Yet beneath the Tempus deal headlines, the combination of widening losses and the company’s history of shareholder dilution is something investors should be aware of...

Personalis' narrative projects $159.7 million revenue and $24.9 million earnings by 2029.

Uncover how Personalis' forecasts yield a $13.88 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming about 34.7% annual revenue growth and continued losses, so this wider than expected H1 2026 net loss may push you to question whether those more pessimistic views on cash burn and dilution risk now feel closer to reality, or whether the recent results could still support a more optimistic path than they assumed.

Explore 2 other fair value estimates on Personalis - why the stock might be worth just $13.88!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Personalis research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Personalis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Personalis' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.